[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563449-105":53,"doc-detail-563449-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","medications-for-weight-loss-in-adults-bc-provincial-academic-detailing-pad-service-march-2024","Medications for Weight Loss in Adults - BC Provincial Academic Detailing (PAD) Service March 2024","","Medications for Weight Loss in Adults from the B.C. Provincial Academic Detailing (PAD) Service (March 2024) provides evidence-informed guidance for prescribing and deprescribing weight-loss drugs in adults. It covers how to choose among tirzepatide, semaglutide, liraglutide, naltrexone-bupropion, and orlistat by comparing dosing, timing of weight-loss effects, response after stopping, and cost considerations. The session also summarizes key contraindications, precautions, and important adverse events, plus clinical context on efficacy outcomes and trial-based weight loss benchmarks.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/medications-for-weight-loss-in-adults-bc-provincial-academic-detailing-pad-service-march-2024/563449/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/medications-for-weight-loss-in-adults-bc-provincial-academic-detailing-pad-service-march-2024/563449.png","ImageObject",442,249,{"name":88,"@type":89},"Asher","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-19","2026-10-12",true,{"@type":98,"interactionType":99,"userInteractionCount":76},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"Which adult weight-loss medications are covered in this PAD session?","Question",{"text":108,"@type":109},"The session focuses on tirzepatide, semaglutide, liraglutide, naltrexone-bupropion, and orlistat for adults considering medications that reduce body weight.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"What factors are discussed for choosing between medications?",{"text":113,"@type":109},"It compares clinical considerations and discusses dosing, dose response, timing of weight-loss effects, what happens after stopping, and cost.",{"name":115,"@type":106,"acceptedAnswer":116},"Does weight loss depend on having gastrointestinal adverse events?",{"text":117,"@type":109},"In semaglutide weight loss trials, weight loss occurs in people both with and without gastrointestinal adverse events; the session notes this may also apply to tirzepatide and liraglutide, though data are more limited.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},563449,1792382413,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":76,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":15,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":79},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Medications for Weight Loss in Adults  \nB.C. Provincial Academic Detailing (PAD) Service March 2024  \nParticipants will have the opportunity to:  \n1. Apply current evidence to guide prescribing and deprescribing decisions for tirzepatide, semaglutide, liraglutide, naltrexone-bupropion and orlistat.  \n2. Compare clinical considerations when choosing between medications.  \n3. Discuss dosing, dose response, timing of weight loss effect, effect after stopping, and cost.  \nThis session will focus on drug information applicable to adults who may be considering medications that reduce body weight. While important, the following are beyond the scope of this session: limitations of body mass index (BMI), pediatrics, nutrition, exercise interventions.  \nPAD acknowledges that there are differences in terminologies regarding body weight and will prioritize language that is respectful of individuals’ preferences.  \n\n| Brand name | Generic name | Year approved |\n| --- | --- | --- |\n| TBD† | tirzepatide subcutaneous once a week | TBD† |\n| Wegovy® | semaglutide subcutaneous once a week | 2021 |\n| Saxenda\u003Cbr>® | liraglutide subcutaneous once a day | 2015 |\n| Contrave® | naltrexone-bupropion oral twice a day | 2018 |\n| Xenical® | orlistat oral\u003Cbr>three times a day | 1999 |\n| † tirzepatide: Health Canada approval for type 2 diabetes in 2022 (Mounjaro®), US Food & Drug Administration approval for chronic weight management in 2023 (Zepbound™) |  |  |\n\nBC’s Provincial Academic Detailing (PAD) Service is offered free of charge to health care professionals. The services is provided by health authorities and supported by the Ministry of Health.  \nRelevant topics are identified in consultation with various groups.  \nTo book an academic detailing session and to subscribe to our PAD Refills newsletter:  \n[www.bcpad.ca](www.bcpad.ca)  \nOverview: pharmacology, contraindications, adverse events  \n2  \n\n| Medication | Basic pharmacology | Contraindications & precautions | Important adverse events |\n| --- | --- | --- | --- |\n| tirzepatide subcutaneous\u003Cbr>Weight Loss: TBD\u003Cbr>Type 2 Diabetes: Mounjaro® | GIP and GLP1 receptor agonist hormone analogue: central and peripheral activity | ▪ medullary thyroid cancer (MTC)\u003Cbr>▪ Multiple Endocrine Neoplasia syndrome type 2 (MEN2)\u003Cbr>▪ pregnancy, breastfeeding\u003Cbr>▪ severe gastrointestinal disease\u003Cbr>▪ type 1 diabetes: not indicated\u003Cbr>▪ tirzepatide: reduces oral contraceptive absorption | ▪ gastrointestinal: nausea > diarrhea > vomiting, constipation; delayed gastric emptying\u003Cbr>▪ pancreatitis, gallbladder disease\u003Cbr>▪ safety reviews ongoing: pulmonary aspiration during surgery; alopecia; suicide, suicidal ideation, self-harm |\n| semaglutide subcutaneous\u003Cbr>Weight Loss: Wegovy®\u003Cbr>Type 2 Diabetes: Ozempic® | GLP1 receptor agonist hormone analogue: central and peripheral activity |  |  |\n| liraglutide subcutaneous\u003Cbr>Weight Loss: Saxenda®\u003Cbr>Type 2 Diabetes: Victoza® |  |  |  |\n| naltrexone-bupropion oral\u003Cbr>Contrave® | naltrexone: opioid antagonist\u003Cbr>bupropion: weak norepinephrine dopamine reuptake inhibitor central activity | ▪ opioid use, including tramadol | ▪ gastrointestinal: nausea > constipation > |\n|  |  | ▪ history or risk of seizures | vomiting, dry mouth |\n|  |  | ▪ uncontrolled hypertension | ▪ agitation type adverse events, insomnia |\n|  |  | ▪ severe liver or kidney dysfunction | ▪ increased blood pressure & heart rate |\n|  |  | ▪ pregnancy, breastfeeding | ▪ safety review ongoing: cardiovascular |\n| orlistat oral\u003Cbr>Xenical® | gastrointestinal lipase inhibitor gastrointestinal activity only | ▪ chronic malabsorption syndrome\u003Cbr>▪ cholestasis\u003Cbr>▪ pregnancy, breastfeeding\u003Cbr>▪ lower gastrointestinal disease | ▪ flatus, oily spotting, fecal incontinence\u003Cbr>▪ oxalate kidney stones, nephropathy\u003Cbr>▪ decreased fat soluble vitamin absorption |\n| GIP: glucose-dependent insulinotropic polypeptide; GLP1 : glucagon-like peptide-1 |  |  |  |\n| A. Mechanism of action: proposed mechanisms of centrally-acting medicati","cbCaimbRUjaER08y","https://ap.wps.com/l/cbCaimbRUjaER08y","pdf",899369,"English","# Session overview\n## Medication selection and scope\n## Terminology and participant-centered language\n# Medication reference tables\n## Brand vs generic and year approved\n## Basic pharmacology and contraindications\n## Important adverse events by medication\n# Clinical efficacy and weight loss outcomes\n## Weight loss trial participant snapshot\n## Expected weight loss at ~1 year\n## Beyond BMI: goals and quality of life","[{\"question\":\"Which adult weight-loss medications are covered in this PAD session?\",\"answer\":\"The session focuses on tirzepatide, semaglutide, liraglutide, naltrexone-bupropion, and orlistat for adults considering medications that reduce body weight.\"},{\"question\":\"What factors are discussed for choosing between medications?\",\"answer\":\"It compares clinical considerations and discusses dosing, dose response, timing of weight-loss effects, what happens after stopping, and cost.\"},{\"question\":\"Does weight loss depend on having gastrointestinal adverse events?\",\"answer\":\"In semaglutide weight loss trials, weight loss occurs in people both with and without gastrointestinal adverse events; the session notes this may also apply to tirzepatide and liraglutide, though data are more limited.\"}]","Medications for Weight Loss in Adults - BC Provincial Academic Detailing (PAD) Service March 2024 | PDF",1791835506]